Clinical Rheumatology

, Volume 26, Issue 2, pp 231–239 | Cite as

Tacrolimus and cyclosporine A inhibit human osteoclast formation via targeting the calcineurin-dependent NFAT pathway and an activation pathway for c-Jun or MITF in rheumatoid arthritis

  • Masashi Miyazaki
  • Yosuke Fujikawa
  • Chikahiro Takita
  • Hiroshi Tsumura
Original Article


In the present study, we aimed to determine whether tacrolimus (FK506) and cyclosporine A act directly on human osteoclast precursors obtained from patients with rheumatoid arthritis (RA) and influence monocyte–osteoclast differentiation induced by receptor activator of NF-κB ligand (RANKL) in vitro, the stage at which differentiation was affected and the manner in which tacrolimus or cyclosporine A affected the osteoclast signaling pathway. Peripheral blood mononuclear cells (PBMCs) were isolated from RA patients and cultured in the presence of RANKL and macrophage-colony stimulating factor (M-CSF). Tacrolimus or cyclosporine A was added to these cultures to determine the effect on the osteoclast differentiation. Osteoclast formation was determined by assessing the number of tartrate resistant acid phosphatase (TRAP) staining cells and measuring the extent of lacunar resorption. The expression of osteoclast transcription factors, such as TNF receptor-associated factor 6 (TRAF6), nuclear factor of activated T cells c1 (NFATc1), c-Fos, c-Jun, microphthalmia transcription factor (MITF) and PU.1 in mononuclear cells (MNCs) was assayed by quantitative reverse transcription-polymerase chain reaction. Addition of tacrolimus or cyclosporine A resulted in a decrease in the number of TRAP-positive multinucleated cells (TRAP+ MNCs) and a decrease in the extent of lacunar resorption pit formation as compared to the control cultures; thus, human monocyte–osteoclast differentiation was more effectively inhibited at the late stage and addition of tacrolimus or cyclosporine A resulted in a decrease in the mRNA expression of NFATc1, c-Jun, and MITF at the late stage. Our results suggest that tacrolimus or cyclosporine A acts directly on human osteoclast precursors in RA patients and exerts their immunosuppressive effects on human monocyte–osteoclast formation via targeting both the calcineurin-dependent NFAT pathway and activation pathway for c-Jun or MITF.


Cyclosporine A NFATc1 Osteoclast Rheumatoid arthritis Tacrolimus 


  1. 1.
    Fujikawa Y, Quinn JM, Sabokbar A, McGee JO, Athanasou NA (1996) The human osteoclast precursor circulates in the monocyte fraction. Endocrinology 137:4058–4060CrossRefPubMedGoogle Scholar
  2. 2.
    Fujikawa Y, Sabokbar A, Neale S, Athanasou NA (1996) Human osteoclast formation and bone resorption by monocytes and synovial macrophages in rheumatoid arthritis. Ann Rheum Dis 55:816–822PubMedCrossRefGoogle Scholar
  3. 3.
    Chaudhuri K, Torley H, Madhok R (1997) Disease-modifying anti-rheumatic drugs. Cyclosporin. Br J Rheumatol 36:1016–1021CrossRefPubMedGoogle Scholar
  4. 4.
    Miyata S, Ohkubo Y, Mutoh S (2005) A review of the action of tacrolimus (FK506) on experimental models of rheumatoid arthritis. Inflamm Res 54:1–9CrossRefPubMedGoogle Scholar
  5. 5.
    Yocum DE, Furst DE, Kaine JL, Baldassare AR, Stevenson JT, Borton MA, Mengle-Gaw LJ, Schwartz BD, Wisemandle W, Mekki QA (2003) Efficacy and safety of tacrolimus in patients with rheumatoid arthritis: a double-blind trial. Arthritis Rheum 48:3328–3337CrossRefPubMedGoogle Scholar
  6. 6.
    Salmon JS, Steiner G (2003) Therapeutic strategies for rheumatoid arthritis. Nat Rev Drug Discov 2:473–488CrossRefPubMedGoogle Scholar
  7. 7.
    Igarashi K, Hirotani H, Woo J-T, Stern PH (2004) Cyclosporine A and FK506 induce osteoclast apoptosis in mouse bone marrow cell cultures. Bone 35:47–56CrossRefPubMedGoogle Scholar
  8. 8.
    Takayanagi H, Kim S, Koga T, Nishina H, Isshiki M, Yoshida H, Saiura A, Isobe M, Yokochi T, Inoue J, Wagener EF, Mak TW, Kodama T, Taniguchi T (2002) Induction and activation of the transcription factor NFATc1 (NFAT2) integrate RANKL signaling in terminal differentiation of osteoclasts. Dev Cell 3:889–901CrossRefPubMedGoogle Scholar
  9. 9.
    Ishida N, Hayashi K, Hoshijima M, Ogawa T, Koga S, Miyatake Y, Kumegawa M, Kimura T, Takeya T (2002) Large scale gene expression analysis of osteoclastogenesis in vitro and elucidation of NFAT2 as a key regulator. J Biol Chem 277:41147–41156CrossRefPubMedGoogle Scholar
  10. 10.
    Takayanagi H (2005) Mechanistic insight into osteoclast differentiation in osteoimmunology. J Mol Med 83:170–179CrossRefPubMedGoogle Scholar
  11. 11.
    Tanaka S, Nakamura I, Inoue J, Oda H, Nakamura K (2003) Signal transduction pathways regulating osteoclast differentiation and function. J Bone Miner Metab 21:123–133CrossRefPubMedGoogle Scholar
  12. 12.
    Gohda J, Akiyama T, Koga T, Takayanagi H, Tanaka S, Inoue J (2005) RANK-mediated amplification of TRAF6 signaling leads to NFATc1 induction during osteoclastogenesis. EMBO J 24:790–799CrossRefPubMedGoogle Scholar
  13. 13.
    Kobayashi N, Kondo Y, Naito A, Matsumoto K, Yamamoto T, Tanaka S, Inoue J (2001) Segregation of TRAF6-mediated signaling pathways clarifies its role in osteoclastogenesis. EMBO J 20:1271–1280CrossRefPubMedGoogle Scholar
  14. 14.
    Ikeda F, Nishimura R, Matsubara T, Tanaka S, Inoue J, Reddy SV, Hata K, Yamashita K, Hiraga T, Watanabe T, Kukita T, Yosioka K, Rao A, Yoneda T (2004) Critical roles of c-Jun signaling in regulation of NFAT family and RANKL-regulated osteoclast differentiation. J Clin Invest 114:475–484CrossRefPubMedGoogle Scholar
  15. 15.
    Teitelbaum SL (2004) RANKing c-Jun in osteoclast development. J Clin Invest 114:463–465CrossRefPubMedGoogle Scholar
  16. 16.
    David JP, Sabapathy K, Hoffamnn O, Idarrage MH, Wagner EF (2002) JNK1 modulates osteoclastogenesis through both c-Jun phosphorylation-dependent and -independent mechanisms. J Cell Sci 115:4317–4325CrossRefPubMedGoogle Scholar
  17. 17.
    Srivastava S, Toraldo G, Weitzmann MN, Cenci S, Ross FP, Pacifici R (2001) Estrogen decreases osteoclast formation by down-regulating receptor activator of NF-kappa B ligand (RANKL)-induced JNK activation. J Biol Chem 276:8836–8840CrossRefPubMedGoogle Scholar
  18. 18.
    Matsuo K, Owens JM, Tonko M, Elliott C, Chambgers TJ, Wagner EF (2000) Fosl1 is a transcriptional target of c-Fos during osteoclast differentiation. Nat Genet 24:184–187CrossRefPubMedGoogle Scholar
  19. 19.
    Obata T, Brown GE, Yaffe MB (2000) MAP kinase pathways activated by stress: the p38 MAPK pathway. Crit Care Med 28:N67–N77CrossRefPubMedGoogle Scholar
  20. 20.
    Mansky KC, Sankar U, Han J, Ostrowski MC (2002) Microphthalmia transcription factor is a target of the p38 MAPK pathway in response to receptor activator of NF-kappa B ligand signaling. J Biol Chem 277:11077–11083CrossRefPubMedGoogle Scholar
  21. 21.
    So H, Rho J, Jeong D, Park R, Fisher DE, Ostrowski MC, Choi Y, Kim N (2003) Microphthalmia transcription factor and PU.1 synergistically induce the leukocyte receptor osteoclast-associated receptor gene expression. J Biol Chem 278:24209–24216CrossRefPubMedGoogle Scholar
  22. 22.
    Matsumoto M, Kogawa M, Wada S, Takayanagi H, Tsujimoto M, Katayama S, Hisatake K, Nogi Y (2004) Essential role of p38 mitogen-activated protein kinase in cathepsin K gene expression during osteoclastogenesis through association of NFATc1 and PU.1. J Biol Chem 279:45969–45979CrossRefPubMedGoogle Scholar
  23. 23.
    Matsuda S, Shibasaki F, Takehana K, Mori H, Nishida E, Koyasu S (2000) Two distinct action mechanisms of immunophilin-ligand complexes for the blockade of T-cell activation.EMBO Rep 1:428–434CrossRefGoogle Scholar
  24. 24.
    Matsuda S, Koyasu S (2000) Mechanisms of action of cyclosporine. Immunopharmacology 47:119–251CrossRefPubMedGoogle Scholar
  25. 25.
    Bostrom A, Bharath H, Saulewicz A, Narayanan AS (2005) Cyclosporin a affects signaling events differentially in human gingival fibroblasts. J Dent Res 84:532–536PubMedCrossRefGoogle Scholar
  26. 26.
    Kim K, Kim JH, Lee J, Jin HM, Lee SH, Fisher DE, Kook H, Kim KK, Choi Y, Kim N (2005) Nuclear factor of activated T cells c1 induces osteoclast-associated receptor gene expression during tumor necrosis factor-related activation-induced cytokine-mediated osteoclastogenesis. J Biol Chem 280:35209–35216CrossRefPubMedGoogle Scholar
  27. 27.
    Kim Y, Sato K, Asagiri M, Morita, Soma K, Takayanagi H (2005) Contribution of nuclear factor of activated T cells c1 to the transcriptional control of immunoreceptor osteoclast-associated receptor but not triggering receptor expressed by myeloid cells-2 during osteoclastogenesis. J Biol Chem 280:32905–32913CrossRefPubMedGoogle Scholar
  28. 28.
    Emmel EA, Verweij CL, Durand DB, Higgins KM, Lacy E, Crabtree GR (1989) Cyclosporin A specifically inhibits function of nuclear proteins involved in T cell activation. Science 246:1617–1620PubMedCrossRefGoogle Scholar
  29. 29.
    Mattila PS, Ullman KS, Fiering S, Emmel EA, McCutcheon M, Crabtree GR, Herzenberg LA (1990) The actions of cyclosporin A and FK506 suggest a novel step in the activation of T lymphocytes. EMBO J 9:4425–4433PubMedGoogle Scholar
  30. 30.
    Ullman KS, Flanagan WM, Edwards CA, Crabtree GR (1991) Activation of early gene expression in T lymphocytes by Oct-1 and an inducible protein, OAP40. Science 254:558–562PubMedCrossRefGoogle Scholar
  31. 31.
    Ullman KS, Northrop JP, Admon A, Crabtree GR (1993) Jun family members are controlled by a calcium-regulated, cyclosporin A-sensitive signaling pathway in activated T lymphocytes. Genes Dev 7:188–196PubMedGoogle Scholar
  32. 32.
    Su B, Jacinto E, Hibi M, Kallunki T, Karin M, Ben-Neriah Y (1994) JNK is involved in signal integration during costimulation of T lymphocytes. Cell 77:727–736CrossRefPubMedGoogle Scholar

Copyright information

© Clinical Rheumatology 2006

Authors and Affiliations

  • Masashi Miyazaki
    • 1
  • Yosuke Fujikawa
    • 1
  • Chikahiro Takita
    • 1
  • Hiroshi Tsumura
    • 1
  1. 1.Department of Orthopaedic Surgery, Faculty of MedicineOita UniversityOitaJapan

Personalised recommendations